Back to News
Market Impact: 0.2
Endovia Health Sciences Closes Initial Funding to Accelerate CannEpil® Development Amid Growing Federal Support for Botanical Drug Pathways
Source: GlobeNewswire
Healthcare & BiotechRegulation & LegislationPrivate Markets & Venture
Endovia has secured financing as the FDA and Congress increase their focus on advancing and incentivizing regulated development of botanical and plant-derived medicines. The funding and supportive policy attention are modestly positive for Endovia and the regulated plant-derived therapeutics sector, although no financing amount or commercial milestones were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
EDVA0.20
More News
- How the US midterm elections reflected resistance to data centres
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- OpenAI to press ahead with data-center expansion despite midterm sweep, CFO tells CNBC
- SoftBank, ABB consider China carve-out to rescue $5.4bn robotics deal
- The race is on to build the first fusion power plant — and Europe is looking to Japan for help
- AI stocks hammered by midterm shock as data center buildout becomes a 'war of attrition'